Clinical study on Evecare forte tablets for the management of Polycystic Ovarian Symdrome (PCOS)

Phase 2

• Conditions: Health Condition 1: null- Female Subjects with Polycystic Ovarian Syndrome

• Registration Number: CTRI/2018/05/014204
• Lead Sponsor: The Himalaya Drug Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Females aged Between 18 years to 45 Years.

2.Women with signs and symptoms of PCOS like irregular menstrual cycles, weight gain, biochemical/clinical hyperandrogenemia, hirsutism etc.

3.History of PCOS with < 8 periods the preceding year.

4.PCOS confirmed by Clinical and or biochemical and or ultrasonographical findings.

5.Willingness to sign consent for study including participation with collection of blood specimens.

Exclusion Criteria

1.Patients who is not using oral contraceptive pills, hormonal treatment or IUCDs.

2.Patients who had no systemic illness like hypertension, renal disease, tuberculosis, hepatic disease, diabetes, coagulation disorder, etc.

3.Patients with organic lesion of the reproductive tract especially any benign or malignant growth, extensive cervical erosion, cervical polyps, endometriosis.

4.Patients with severe Hepatic or cardiac or mental illness.

5.Patients unwilling to provide informed consent or abide by the requirements of the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified